Post by
subaru1i on Mar 28, 2024 9:50am
For North America, where LABS is located with their
'traditional' global pharm partner, the REAL value of LABS is unlocked by DEA rescheduling, opening the path for pharmaceuticals to be commercialized after FDA approval. Management in the CC specifically made mention of the Libby Study at U of Southern California, funded by the NIH and allowed to happen by DEA exports permits issued to LABS to cross the border.
LABS on the global stage has already shownn itself to be a 'funnel' with their one of a kind FDA and Health Canada certifications enabling non North American pharmaceutical companies to advance their cannabinoid based pharmaceutical goals.
They are the 'go to' company. Accretive means adding the capabilities of LABS portfolio into the capabilities of Pfizer CentreOne.
But Pfizer was smart.....they have over 20 strong clinical trials with LABS already targeting a vareity of human diseases including cancer.
We will see soon this picture once DEA reschedules.
The entire CC yesterday in it's entirety was to provide more 'color' to the bigger picture and their traditional pharma partner.
It's good to dig into the details but one also needs to balance that perspective by standing further back and question...what does it all mean within the bigger global business picture.
alleyesonme...unfortunately we have to wait for the DEA but it is a function of LABS being located in Canada and their traditional partner being located in the U.S.
Also: Germany proved it's not impossible to do and Keith (already have more inside information to the DEA process) stated, new strict rules with FDA over sight....pharmaceuticals!!!